A Phase 3 interventional study of Sodium Zirconium Cyclosilicate and Placebo in Hyperkalemia, sponsored by AstraZeneca. Completed at 36 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-03-28.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 11th largest by enrollment, is the only one that started in 2020, is one of 12 in phase 3, and was the 11th registered.
134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.
Browse Hyperkalemia studies →3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:
AstraZeneca · Sites in India
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Qianfoshan Hospital
Ages 18–75
By country, each count listing its studies:
sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 13 · Phase 4 6
First in 2014; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 88 across 103 interventional studies indexed under Hyperkalemia.
Median enrollment 120 across the 27 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 27 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
39 studies in Hyperkalemia by AstraZeneca: 2 open now, 3 under way, 1 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 39 studies in Hyperkalemia by AstraZeneca, this one is the 15th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2020, is one of 13 in phase 3, and was the 19th registered.
AstraZeneca’s Hyperkalemia studies by the year they started, since 2011.
2 of the studies testing sodium zirconium cyclosilicate in Hyperkalemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736184Qianfoshan HospitalThe Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients | 2026-12-31 |
| NCT07944378AstraZenecaA Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, from their registry updates:
Among AstraZeneca’s 39 in Hyperkalemia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Sodium Zirconium Cyclosilicate (SZC), as well as the appropriateness of the dosing mechanism, in Chinese end-stage renal disease (ESRD) patients on chronic haemodialysis.
This is a randomized, double-blind, placebo-controlled study to determine the safety and efficacy of SZC in ESRD subjects with hyperkalaemia and on stable haemodialysis. This study consists of a screening period, an 8-week randomized treatment period, and a follow-up period. Approximately 134 stable haemodialysis subjects with persistent pre-dialysis hyperkalaemia will be enrolled in the study across research sites in China.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
Drug: Sodium Zirconium Cyclosilicate
Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
Drug: Placebo
Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
Also known as: SZC; Lokelma; ZS
Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
Percentage of Responders
A subject was considered to be a responder if, during the evaluation period, they maintained a pre-dialysis serum potassium (S-K) between 4.0 and 5.0 mmol/L on at least 3 out of 4 dialysis treatments following the long inter-dialytic interval (LIDI) and did not receive rescue therapy. Subjects with no data during the evaluation period were classified as non-responders. The S-K levels used for this analysis were based on the measurements obtained by the central laboratory.
Time frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.
Maximum Pre-dialysis S-K Values After SIDI and LIDI Below or Equal to 5.5 mmol/L During Evaluation Period
Probability of maintaining maximum S-K value \<= 5.5 mmol/L was evaluated. Each subject's maximum pre-dialysis S-K at long inter-dialytic interval (LIDI) and short inter-dialytic interval (SIDI) visits during the evaluation period were categorised into \<= 5.5 or \> 5.5 mmol/L. Missing S-K values including those omitted due to coinciding with rescue therapy use or records omitted that are not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were imputed using multiple imputation (MI).
Time frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.
Pre-dialysis S-K After LIDI Between 3.5 and 5.5 mmol/L During the Evaluation Period
Probability of all S-K values between 3.5 and 5.5 mmol/L was evaluated. Subjects were categorised to either having all pre-dialysis LIDI values between 3.5 and 5.5 mmol/L during the evaluation period or not. Missing S-K values including those omitted due to coinciding with rescue therapy use or records omitted that are not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were imputed using multiple imputation (MI).
Time frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.
Instances of Pre-dialysis S-K After LIDI Between 4.0 and 5.0 mmol/L During the Evaluation Period
The probability of maintaining instances of pre-dialysis S-K between 4.0 and 5.0 mmol/L (normokalaemia) was evaluated at each LIDI visit during the evaluation period, by categorisation of pre-dialysis S-K into values between 4.0 and 5.0 mmol/L or not. Values coinciding with rescue therapy or not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were excluded.
Time frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.
Expected Number of Normokalaemic (S-K 4.0-5.0 mmol/L) Instances
The expected number of normokalemic instances is the sum of the probabilities of normokalaemic instance at each visit during the evaluation period. Normokalaemic is defined as S-K between 4.0 and 5.0 mmol/L.
Time frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.
Instances of Potassium Gradient of < 3.0 mmol/L After LIDI During the Evaluation Period
The probability of maintaining instances of potassium gradient of \< 3.0 mmol/L was evaluated at each LIDI visit during the evaluation period, by categorisation of potassium gradient into \< 3.0 or \>=3.0 mmol/L. Values coinciding with rescue therapy or not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were excluded.
Time frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks.
The study has been completed and was conducted in 37 centres across China. 281 subjects were screened and 134 randomised subjects (67 per treatment group).
| Milestone | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| Started | 67 | 67 |
| Completed | 63 | 64 |
| Not completed | 4 | 3 |
| Withdrew: Other | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Death | 0 | 1 |
A subject was considered to be a responder if, during the evaluation period, they maintained a pre-dialysis serum potassium (S-K) between 4.0 and 5.0 mmol/L on at least 3 out of 4 dialysis treatments following the long inter-dialytic interval (LIDI) and did not receive rescue therapy. Subjects with no data during the evaluation period were classified as non-responders. The S-K levels used for this analysis were based on the measurements obtained by the central laboratory.
| Participants | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| Percentage of Responders | 25 | 7 |
Probability of maintaining maximum S-K value \<= 5.5 mmol/L was evaluated. Each subject's maximum pre-dialysis S-K at long inter-dialytic interval (LIDI) and short inter-dialytic interval (SIDI) visits during the evaluation period were categorised into \<= 5.5 or \> 5.5 mmol/L. Missing S-K values including those omitted due to coinciding with rescue therapy use or records omitted that are not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were imputed using multiple imputation (MI).
| Probability | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| Maximum Pre-dialysis S-K Values After SIDI and LIDI Below or Equal to 5.5 mmol/L During Evaluation Period | 0.54 | 0.15 |
Probability of all S-K values between 3.5 and 5.5 mmol/L was evaluated. Subjects were categorised to either having all pre-dialysis LIDI values between 3.5 and 5.5 mmol/L during the evaluation period or not. Missing S-K values including those omitted due to coinciding with rescue therapy use or records omitted that are not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were imputed using multiple imputation (MI).
| Probability | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| Pre-dialysis S-K After LIDI Between 3.5 and 5.5 mmol/L During the Evaluation Period | 0.58 | 0.17 |
The probability of maintaining instances of pre-dialysis S-K between 4.0 and 5.0 mmol/L (normokalaemia) was evaluated at each LIDI visit during the evaluation period, by categorisation of pre-dialysis S-K into values between 4.0 and 5.0 mmol/L or not. Values coinciding with rescue therapy or not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were excluded.
| Probability | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| Instances of Pre-dialysis S-K After LIDI Between 4.0 and 5.0 mmol/L During the Evaluation Period | 0.48 | 0.17 |
The expected number of normokalemic instances is the sum of the probabilities of normokalaemic instance at each visit during the evaluation period. Normokalaemic is defined as S-K between 4.0 and 5.0 mmol/L.
| Sum of probabilities | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| Expected Number of Normokalaemic (S-K 4.0-5.0 mmol/L) Instances | 1.91 | 0.70 |
The probability of maintaining instances of potassium gradient of \< 3.0 mmol/L was evaluated at each LIDI visit during the evaluation period, by categorisation of potassium gradient into \< 3.0 or \>=3.0 mmol/L. Values coinciding with rescue therapy or not true LIDI (i.e. records which do not occur \>= 55 hours after the previous dialysis starting time) were excluded.
| Probability | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| Instances of Potassium Gradient of < 3.0 mmol/L After LIDI During the Evaluation Period | 0.52 | 0.16 |
Collected over Includes adverse events that occurred from time of randomization throughout the treatment period and follow-up period, up to end of study visit (Day 71 +/- 3 days) or premature study discontinuation visit.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sodium Zirconium Cyclosilicate (SZC) | 0/66 (0%) | 6/66 (9.1%) | 24/66 (36.4%) |
| Placebo | 1/67 (1.5%) | 8/67 (11.9%) | 25/67 (37.3%) |
| Event | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 0/66 | 3/67 |
| Traumatic renal injuryInjury, poisoning and procedural complications | 1/66 | 0/67 |
| SpondylolisthesisMusculoskeletal and connective tissue disorders | 1/66 | 0/67 |
| Cardiac failureCardiac disorders | 1/66 | 0/67 |
| SynovitisMusculoskeletal and connective tissue disorders | 1/66 | 0/67 |
| Haemorrhagic gastroenteritisGastrointestinal disorders | 1/66 | 0/67 |
| Cholangitis acuteHepatobiliary disorders | 1/66 | 0/67 |
| PneumoniaInfections and infestations | 0/66 | 1/67 |
| Arteriovenous fistula occlusionInjury, poisoning and procedural complications | 0/66 | 1/67 |
| Brain stem haemorrhageNervous system disorders | 0/66 | 1/67 |
| Event | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 7/66 | 6/67 |
| ConstipationGastrointestinal disorders | 6/66 | 2/67 |
| Upper respiratory tract infectionInfections and infestations | 4/66 | 1/67 |
| Dialysis hypotensionVascular disorders | 3/66 | 4/67 |
| DizzinessNervous system disorders | 3/66 | 0/67 |
| HeadacheNervous system disorders | 3/66 | 2/67 |
| HypotensionVascular disorders | 3/66 | 3/67 |
| AcidosisMetabolism and nutrition disorders | 0/66 | 3/67 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/66 | 3/67 |
| Metabolic acidosisMetabolism and nutrition disorders | 2/66 | 3/67 |
Baseline analysis was based on all patients in the full analysis set (FAS), which comprised all patients randomized. Patients were included in the analysis in the treatment arm to which they were randomized, regardless of the treatment they received.
| Age, Continuous(Years) | Sodium Zirconium Cyclosilicate (SZC) | Placebo | Total |
|---|---|---|---|
| Mean | 54.9 ± 11.32 | 54.5 ± 11.36 | 54.7 ± 11.30 |
| Age, Customized(Participants) | Sodium Zirconium Cyclosilicate (SZC) | Placebo | Total |
|---|---|---|---|
| Age group (years) — <50 years | 20 | 22 | 42 |
| Age group (years) — >=50 - <65 years | 33 | 33 | 66 |
| Age group (years) — >=65 -<85 years | 14 | 11 | 25 |
| Age group (years) — >=85 years | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | Sodium Zirconium Cyclosilicate (SZC) | Placebo | Total |
|---|---|---|---|
| Female | 34 | 34 | 68 |
| Male | 33 | 33 | 66 |
| Race/Ethnicity, Customized(Participants) | Sodium Zirconium Cyclosilicate (SZC) | Placebo | Total |
|---|---|---|---|
| Asian | 67 | 67 | 134 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2020 to primary completion in Jan 2022, 13 months.
Results were first posted in Mar 2023, 1 year 2 months after primary completion.
Of 18 phase 3 interventional studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium zirconium cyclosilicate